We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Somatostatin Analogs on Prostate Volume.
- Authors
KOSTEK, Osman; HACIOGLU, Muhammet Bekir
- Abstract
Objective: Somatostatin is an acidic peptide that has mainly inhibitory function in the endocrine system. We aimed to evaluate whether there is a dimensional change in prostate in patients with gastrointestinal neuroendocrine tumors (NET) treated with somatostatin analogues. Methods: Most of the patients were given 30 mg IM long-acting octreotide acetate at 4-week intervals for the treatment of neuroendocrine tumor. Only 1 patient received 120 mg of another long-acting somatostatin analog subcutaneously every 4 weeks. Baseline and follow-up CT studies of the patients who were under treatment with somatostatin analogs were performed. Results: A total of 15 NET patients who received somatostatin analogs were analyzed. Thirteen (86.6%) patients had reduced prostate volume after somatostatin analog use. Median reduction in the volume of prostate was 5.66 (1.97-9.60) cc with somatostatin analog use (median treatment time was 3.2, 2.8-8.6 months). Median overall survival was 34.8 months (95%% CI 13.8-55.9) in all patients. It was 36.1 months (95% CI 9.5-62.7) in patients with reduced prostate volume and 21.7 (95% CI 6.9-36.5) months in those whose prostate volumes remained unchanged (p=0.14). Conclusions: interestingly, Somatostatin analogue therapy has decreased prostate volumes in NET patients. Potential therapeutic role of somatostatin analogs in the treatment of benign prostat hyperplasia patients might be evaluated in prospective studies.
- Subjects
SOMATOSTATIN; ENDOCRINE system; PROSTATE; OCTREOTIDE acetate; NEUROENDOCRINE tumors
- Publication
Medeniyet Medical Journal, 2019, Vol 34, Issue 2, p176
- ISSN
2149-2042
- Publication type
Article
- DOI
10.5222/MMJ.2019.47700